NICE rejects 2 drug combos for a certain type of breast cancer:

12/14/2010 | Google

Draft guidance issued by the U.K.'s National Institute for Health and Clinical Excellence does not endorse the use of GlaxoSmithKline's Tyverb or Roche Holding's Herceptin in addition to an aromatase inhibitor for women with hormone-receptor and HER2-positive breast cancer. "The evidence suggests that these drug combinations do not offer enough additional value to patients over and above currently available treatment to justify the high cost that the [National Health Service] would have to pay for them," NICE CEO Andrew Dillon said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Chicago, IL
Senior Manager, Compliance
Fremont, CA
Manager, Business Conduct
Foster City, CA
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA